The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

References

• Garcia-Manero G, Fader! S, O'Brien S, Cortes J, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 2003;98:437–457.
   PubMed Web of Science ®Google Scholar
• Goldman J, Melo J. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451–1464.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukemia. N Engl J Med 2003;348:994–1004.
   Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O'Brien S, Smith TL, Giles FJ, Fader! S, Thomas DA, Garcia-Manero G, Issa J-PJ, Andreeff M et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002;8:2177–2187.
   Google Scholar
• Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 200299:1928-1937.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Fader! S, Thomas D, Jeha S, Rios MB, Letvak L et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leu-kemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101:97–100.
   Google Scholar
• Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood2004;103:2873–2878.
   Google Scholar
• Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Fader! S, Thomas D, Giles F, Rios MB, Shan J, Arlinghaus R. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9: 160–166.
   Google Scholar
• Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–1432.
   PubMed Web of Science ®Google Scholar
• Anstrom K, Reed S, Glendenning G, Foster J, Hensley M, Schulman K for the IRIS Study Team. Estimated long-term survival benefit of imatinib therapy in patients with newly diagnosed chronic myeloid leukemia [abstract]. J Clin Oncol (Suppl.) 2003;22:589.
   Google Scholar
• Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Fader! S, Garcia-Manero G, Ferrajoli A, Wierda W et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic mye-logenous leukemia. Cancer 2003;98:1105–1113.
   Google Scholar
• Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 1987;59:1739–1743.
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, Leder LD, Schaefer HE. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1 +) chronic myelo-genous leukemia: a multicenter trial. J Clin Oncol 2001;19: 2994–3009.
   Google Scholar
• Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, Pfirrmann M, Gomez G, Tobler A, Herrmann H et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia 2003;17:2444–2453.
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Bueso-Ramos C, O'Brien S, Pierce S, Keating M, Talpaz M, Kantarjian HM. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia 1998;12:65–70.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Niederle N, Zirbes TK, Schmidt M, Dammasch J, Meuter BR, Leder L-D, Kloke O, Diehl Vet al. The impact of interferon versus busulfan therapy on the reticulin stain measured fibrosis in CML - a comparative morphometric study on sequential trephine biopsies. Ann Hematol 1995;70:121–128.
   Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Graeff A, Spohr M, Diehl V, Zankovich R, Niederle N, Leder L-D. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multi-center histological and clinical study. Br J Haematol 2000;108:64–71.
   Google Scholar
• Bueso-Ramos CE, Cortes J, Talpaz M, O'Brien S, Giles F, Rios MB, Medeiros LJ, Kantarjian H. Imatinib mesylate therapy reduces bone marrow fibrosis in chronic myelogenous leukemia. Cancer 2004;101:332–336.
   Google Scholar
• Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Höfler G, Haas OA, Linkesch W. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99: 381–383.
   Google Scholar
• Hasserjian P, Boecklin F, Parker S, Chase A, Dhar S, Zaiac M, Olavarria E, Lampert I, Henry K, Apperley JF et al. STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytoge-netic response. Am J Clin Pathol 2002;117:360–367.
   PubMed Web of Science ®Google Scholar
• Kaban K, Kantarjian H, Talpaz M, O'Brien S, Cortes J, Giles F, Pierce S, Albitar M. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correla-tion with disease progression and response to therapy. Cancer 2000;88:570— 576.
   Google Scholar
• Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 1991;78:2400 — 2406.
   PubMed Web of Science ®Google Scholar